Reliable and traceable starting materials, such as high-quality human induced pluripotent stem cell (hiPSC) lines, are essential for enabling reproducible PSC-derived cell therapy development. However, many RUO materials are generated under donor, consent, or process constraints that prevent rederivation under GMP conditions, which limits their suitability for clinical translation.

To address these challenges, LineaBio has introduced the GMP hiPSC lines, Linea 1 and Linea 2, produced under defined, quality-controlled processes. In partnership with STEMCELL Technologies, matched RUO equivalents are derived from the same source material and qualified to meet or exceed ISSCR standards. Selecting matched starting materials enables smoother advancement through development stages and lowers the likelihood of requiring process redesign at later phases.

Watch this webinar to learn how LineaBio’s GMP manufacturing framework, combined with STEMCELL’s rigorous quality control for matched RUO cell lines, can support your PSC-derived cell therapy development. You may also sign up to be notified when these products launch.